Total
0
Shares
Recce Pharmaceuticals (RCE) - ‎Chief Scientific Officer and Executive Director Michele Dilizia
‎Chief Scientific Officer and Executive Director Michele Dilizia
Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • A recent study finds Recce Pharmaceutical’s (RCE) R327 candidate to demonstrate “outstanding efficacy” against flesh-eating bacteria
  • The study found RCE’s synthetic anti-infective reduced the “flesh-eating” bacterial count of necrotizing fasciitis
  • Data from the study is also evidence of the candidate’s potential against diabetic wounds and infected ulcers
  • Recce’s Chief Scientific Officer Michele Diliza said the candidate could significantly change the treatment paradigm and save lives
  • Recce Pharmaceuticals shares were up 6.59 per cent to trade at 97 cents

A recent study has found Recce Pharmaceutical’s (RCE) R327 candidate to demonstrate “outstanding efficacy” against flesh-eating bacteria.

An independent study was conducted to test RCE’s synthetic anti-infective R327 against two strains of necrotizing fasciitis — a life-threatening bacterial infection with a mortality rate of up to 80 per cent.

The study found R327 reduced deadly ‘flesh-eating’ bacterial count Below Limit of Quantification (BLOQ) within 24 hours and demonstrated efficacy 30 minutes into testing.

Broadly, RCE said the data demonstrate R327’s potential against bacterial infections that thrive in nil to low oxygen environments such as diabetic wounds and ulcers infections.

Recce Pharmaceuticals Chief Scientific Officer Michele Diliza said necrotizing fasciitis can lead to serious complications and is challenging for physicians and families alike.

“A broad-spectrum anti-infective with rapid efficacy has the potential to significantly change the treatment paradigm and save lives,” he said.

“We have been thoroughly impressed with the efficacy that R327 has demonstrated thus far, as it reinforces our belief in the potential of this compound against such aggressive, life-threatening bacteria.”

Recce Pharmaceuticals shares were up 6.59 per cent to trade at 97 cents at 2:35 pm AEST.

RCE by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening